A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Meeting Abstract
| Authors: | Cook, R. J.; Stein, E.; Steensma, D. P.; Sekeres, M. A.; Bixby, D. L.; Rizzieri, D.; Jurcic, J. G.; Vigil, C. E.; Redner, R.; Roboz, G. J.; Savona, M. R.; McKeown, M. R.; Stephens, K.; Roth, D. A.; Cortes, J. E. |
| Abstract Title: | A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 390s |
| Language: | English |
| ACCESSION: | WOS:000411931708101 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.TPS7071 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS7071 -- Source: Wos |
